Trial
NCT02451111
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
Nordic Lymphoma Group
Condition
Follicular Lymphoma
Intervention
Ibrutinib
Why stopped
The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-13